Cumberland Pharmaceuticals Inc.
CPIX
$4.76
$0.235.08%
NASDAQ
| 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | 12/31/2023 | |
|---|---|---|---|---|---|
| Revenue | 9.11M | 9.09M | 9.85M | 8.50M | 7.31M |
| Total Other Revenue | 1.33M | -- | -- | -- | 2.04M |
| Total Revenue | 10.44M | 9.09M | 9.85M | 8.50M | 9.35M |
| Cost of Revenue | 1.98M | 1.32M | 1.71M | 1.58M | 1.53M |
| Gross Profit | 8.46M | 7.76M | 8.14M | 6.92M | 7.82M |
| SG&A Expenses | 7.55M | 7.07M | 7.01M | 6.52M | 8.20M |
| Depreciation & Amortization | 1.46M | 1.08M | 1.10M | 1.11M | 1.20M |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 12.28M | 10.78M | 10.88M | 10.37M | 12.19M |
| Operating Income | -1.84M | -1.69M | -1.03M | -1.87M | -2.84M |
| Income Before Tax | -1.96M | -1.53M | -1.09M | -1.89M | -6.28M |
| Income Tax Expenses | -57.00K | 11.40K | 11.40K | 11.40K | 25.00K |
| Earnings from Continuing Operations | -1.90M | -1.54M | -1.10M | -1.90M | -6.30M |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -2.20K | -7.10K | 17.00K | -43.80K | 7.60K |
| Net Income | -1.90M | -1.54M | -1.09M | -1.95M | -6.29M |
| EBIT | -1.84M | -1.69M | -1.03M | -1.87M | -2.84M |
| EBITDA | -345.60K | -578.40K | 112.80K | -718.60K | -1.60M |
| EPS Basic | -0.14 | -0.11 | -0.08 | -0.14 | -0.44 |
| Normalized Basic EPS | -0.09 | -0.08 | -0.05 | -0.09 | -0.13 |
| EPS Diluted | -0.14 | -0.11 | -0.08 | -0.14 | -0.45 |
| Normalized Diluted EPS | -0.09 | -0.08 | -0.05 | -0.09 | -0.13 |
| Average Basic Shares Outstanding | 13.97M | 14.05M | 14.12M | 14.10M | 14.16M |
| Average Diluted Shares Outstanding | 13.97M | 14.05M | 14.12M | 14.10M | 14.16M |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |